Aarti Pharmalabs Limited has announced that a meeting of its Board of Directors is scheduled for May 18, 2026. The board will review and approve the audited financial results for the quarter and the full financial year ending March 31, 2026. Additionally, the directors will consider the recommendation of a final dividend for shareholders for the same fiscal period.
Board Meeting Agenda
Aarti Pharmalabs Limited has formally notified the stock exchanges that its Board of Directors will convene on May 18, 2026. The primary focus of this meeting is to review and provide final approval for the audited financial performance of the company for the quarter and the full financial year concluded on March 31, 2026. These results will have been previously scrutinized by the company’s Audit Committee.
Dividend Consideration
Beyond the financial results, the board is also set to discuss and potentially recommend a final dividend for the financial year ended March 31, 2026. Any dividend declaration is subject to the approval of shareholders at the upcoming annual general meeting.
Trading Window Update
In accordance with the company’s internal code of conduct for preventing insider trading, the trading window for securities has been closed since April 1, 2026. This restriction on trading by company insiders will remain in effect until May 20, 2026, ensuring the confidentiality of the financial outcomes until they are officially made public.
Source: BSE
